Skip to main content
. 2023 Jan 12;13:1020844. doi: 10.3389/fimmu.2022.1020844

Figure 3.

Figure 3

Anti-S1 serum and salivary IgA levels. (A-C) Anti-S1 serum IgA levels (ratios to reference value) of the indicated six vaccination groups. (D) Color legend of the six study groups. (E-G) Anti-S1 salivary IgA levels (OD 450 nm values) of the indicated six groups. Gray bars: time windows of the second shot after the first shot with an mRNA (between day 21 and 45) or adenovirus-based (between day 70 and 84) vaccine. Dashed and dotted lines indicate the corresponding anti-S1 IgA average levels of pre-infected individuals without/before vaccination or non-vaccinated healthy (negative) controls, respectively. (H, I) Pearson correlations between anti-S1 serum IgA and salivary IgA levels (y-axis as in (E)) of all paired samples from once and twice BNT162b2-vaccinated naïve and pre-infected individuals. p-values of the indicated correlations are shown.